C-C motif chemokine ligand 2

Overview

C-C motif chemokine ligand 2 (CCL2), widely known as monocyte chemoattractant protein-1 (MCP-1), is a small secreted cytokine belonging to the CC chemokine family. It is encoded by the CCL2 gene and functions primarily as a potent chemoattractant that recruits monocytes, memory T cells, and dendritic cells to sites of tissue injury, infection, and inflammation. CCL2 exerts its effects predominantly through binding to its cognate receptor CCR2, triggering downstream signaling cascades that promote immune cell trafficking across vascular endothelium into inflamed tissues. As a central mediator of the innate and adaptive immune response, CCL2 is constitutively expressed at low levels in a wide range of cell types — including endothelial cells, smooth muscle cells, fibroblasts, astrocytes, and adipose-derived stem cells — and is rapidly upregulated in response to proinflammatory stimuli such as Tumour necrosis factor alpha (TNF-α), interleukin-1 beta, interleukin-6, and nuclear factor kappa B (NF-κB) activation.

Beyond its canonical role in monocyte recruitment, CCL2 has emerged as a pleiotropic signaling molecule with relevance across a broad spectrum of pathological conditions, including sepsis, chronic kidney disease, lupus nephritis, obesity-associated inflammation, periodontitis, spinal cord injury, diabetic wound healing, and cancer. Its intersection with oxidative stress pathways, matrix metalloproteinase activity (notably matrix metalloproteinase-9), and growth factors such as TGF-β1 positions it as a critical node in the inflammatory-fibrotic axis. Dysregulated CCL2 expression is increasingly recognized as both a biomarker of disease severity and a tractable therapeutic target, making it a subject of intense contemporary biomedical research.

Focus of Latest Publications

Recent publications have continued to examine C-C motif chemokine ligand 2 (CCL2) as a therapeutic target in cancer, inflammatory disease, and tissue repair. In breast cancer, one study developed chimeric CCL2- and CCL8-diphtheria toxin cytotoxic peptides to overcome ligand-receptor redundancy and evaluate antitumor activity against human breast tumors. Another breast cancer study used a mesoporous silica nanoparticle system modified with lysine and cysteine to deliver CRISPR-Cas plasmids targeting the MCP-1/CCL2 gene; suppression of CCL2 was reported to reduce proliferation, migration, and invasion of MDA-MB-231 cells. In lung adenocarcinoma, CCL2 was implicated mechanistically as part of a CCL2 axis through which GINS1 promoted M2 macrophage polarization, immune exclusion, and T-cell exhaustion, linking CCL2-associated signaling to tumor progression and poor response to checkpoint inhibitor therapy.

CCL2 was also investigated in inflammatory and autoimmune settings. In lupus nephritis, MCP-1/CCL2 was described as a critical mediator of monocyte recruitment and renal inflammation, and a nanoinformatics-guided design study proposed folic acid-functionalized fullerene nanostructures as potential MCP-1 inhibitors, with docking suggesting improved binding affinity and a low predicted toxicity profile. In periodontitis, a systematic review and meta-analysis found significantly elevated systemic CCL2 levels compared with controls, including in analyses restricted to systemically healthy participants, supporting an association between periodontitis and broader inflammatory dysregulation. A separate study of strength training during chemotherapy in women with breast cancer measured serum MCP-1 among other cytokines, but reported no change in MCP-1 with the intervention.

Other recent work highlighted CCL2 in regenerative and transplant-related contexts. Single-cell sequencing identified a CCL2-expressing adipose-derived stem cell subpopulation that promoted diabetic wound healing through the CCL2-ACKR1 signaling axis; exosomes from these cells were enriched in CCL2 and accelerated wound closure in mice, promoting angiogenesis, collagen deposition, M2-macrophage polarization, and endothelial cell function, with effects dependent on CCL2 and ACKR1. In transplantation, anti-CCL2-conjugated platelets were studied as a strategy to attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration. Together, these publications portray CCL2 as a recurring target in studies of tumor biology, immune-mediated injury, and tissue repair, with approaches ranging from cytotoxic peptides and CRISPR-Cas methods to nanoparticle-based inhibitors and extracellular vesicle therapies.

Key Publications

• NEWJul Effective treatment of human breast tumors by chimeric CCL2 and CCL8 diphtheria toxin cytotoxic peptides. (Cancer biology & therapy, 2026, PMID 42390481): "To overcome this limitation, we developed chimeric chemokine peptides in which CCL2 and CCL8 were conjugated to diphtheria toxin (DT) and evaluated their antitumor activity."
• NEWJul Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration. (Journal of hepatology, 2026, PMID 42385858): "Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration."
• NEWJul The Effect of Strength Training During Chemotherapy in Women With Breast Cancer on Serum Cytokine Concentrations and Skeletal Muscle Autophagy-Related Proteins. (European journal of sport science, 2026, PMID 42350900): "Serum cytokines (IFN-γ, IL-1RA, IL-6, IL-8, IL-10, IL-17, MCP-1, TNF-α) were quantified, and muscle biopsies were analyzed for autophagy- and heat-shock-related proteins."
• NEWJun Multi-omics analysis identifies GINS1 as a prognostic biomarker in lung adenocarcinoma, linked to macrophage polarization and tumor cell survival. (Discover oncology, 2026, PMID 42295485): "Mechanistically, GINS1 promotes an immunosuppressive microenvironment by driving M2 macrophage polarization via the C-C Motif Chemokine Ligand 2(CCL2) axis and fostering T-cell exhaustion and immune exclusion."
• May Nanoinformatics-guided design and molecular dynamic evaluation of folic acid-functionalized fullerene therapies for lupus nephritis in women. (Journal of molecular modeling, 2026, PMID 42118345): "Monocyte chemoattractant protein-1 (MCP-1/CCL2) plays a critical role in the pathogenesis of LN by promoting monocyte recruitment and sustaining renal inflammation."
• May Single-Cell Sequencing Reveals That CCL2+ Adipose-Derived Stem Cells Promote Diabetic Wound Healing Through the CCL2-ACKR1 Signaling Axis. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42033160): "Using single-cell RNA sequencing of human adipose and diabetic wound tissues, we identified a distinct CCL2-expressing ADSC subpopulation that is enriched in obese individuals and exhibits elevated stemness, unique metabolic profiles, and enrichment in pathways related to ECM organization and tissue development."
• Apr Systemic Cytokine Alterations in Periodontitis Independent of Comorbidities: A Systematic Review and Meta-Analysis. (Aging and disease, 2026, PMID 41910651): "analyses showed significantly (P<0.05) higher levels of C-C motif chemokine ligand 2 (CCL2); interleukin (IL)-1β, IL-6, IL-17, IL-17A and IL-18; leptin; matrix metalloproteinase 8 (MMP-8), myeloperoxidase (MPO); receptor activator of nuclear factor kappa-Β ligand (RANKL); and tumour necrosis factor α (TNF-α)."
• Apr The MCM/Lys-Cys nanodevices for the efficient gene delivery: An approach towardsMCP1gene manipulation using CRISPR technology. (Colloids and surfaces. B, Biointerfaces, 2026, PMID 41443126): "This research investigates an innovative gene delivery strategy employing mesoporous silica nanoparticles (MCM-41) modified with lysine and cysteine (Lys-Cys) for the effective delivery of CRISPR-Cas9 plasmids aimed at the monocyte chemoattractant protein-1 (MCP-1/CCL2) gene."